In a series of updates, Amgen (AMGN) has announced its second quarter dividend for 2025. The company's stock has seen an increase of 2.9% since their most recent earnings report, while it enters late-stage testing for a new weight loss drug, proving itself as a potentially undervalued stock worth investment. Also, promising Phase 3 results were announced for their drug Rocatinlimab which treats Atopic Dermatitis. The company has garnered investment attention with numerous investment groups increasing their stakes in Amgen. The company is also tipped as outperforming others in the healthcare sector. Notably, it has invested $200M in an AI-based Tech center in India, aiming to hire 2,000 employees by 2025. A new obesity drug they have been trialing is also making a big impact. Following fourth-quarter and full-year financial results in 2024, the company declared $2.38 quarterly dividends. The company's strategic growth is significantly bolstered by its drug MariTide’s Phase III trials. Lastly, CEO Bradway is slated to present Q4 earnings and strategical vision in February.
Amgen AMGN News Analytics from Wed, 30 Oct 2024 07:00:00 GMT to Sat, 08 Mar 2025 20:06:16 GMT - Rating 7 - Innovation 8 - Information 8 - Rumor 6
